Samir H Moussa

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 9

Top Venues

Antimicrobial agents and chemotherapy

Open forum infectious diseases

Nature microbiology

Entasis Therapeutics

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Entasis Therapeutics

United States

Senior Scientist, Bacterial Genetics

Harvard Medical School

United States

Research Fellow :: Microbiology and Immunobiology (MBIB)

Publications

Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa, Adam B Shapiro
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open forum infectious diseases 11 (4) (2024)
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa, Adam B Shapiro
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open forum infectious diseases 11 (4) (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Samir H Moussa, Adam B Shapiro, Sarah M McLeod, Ramkumar Iyer, Nicole M Carter, Yu-Kuo Tsai, L Kristopher Siu, Alita A Miller
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii . Antimicrobial agents and chemotherapy (2023)
Thomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, Brendan Chen, Neil Bifulco, Hoan Huynh, Sushmita Lahiri, Adam B Shapiro, Sarah M McLeod, Nicole M Carter, Samir H Moussa, Camilo Velez-Vega, Nelson B Olivier, Robert McLaughlin, Ning Gao, Jason Thresher, Tiffany Palmer, Beth Andrews, Robert A Giacobbe, Joseph V Newman, David E Ehmann, Boudewijn de Jonge, John O'Donnell, John P Mueller, Rubén A Tommasi, Alita A Miller
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nature microbiology 2 (2017)

Samir H Moussa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Samir H Moussa